MET and non-small cell lung carcinoma: Amivantamab, available under the brand name Rybrevant, is a human IgG1-based bispecific monoclonal antibody which simultaneously targets both EGFR and the mesenchymal–epithelial transition (MET) receptor expressed on the surface of epithelial cells in non-small-cell lung cancer (NSCLC).